Clene goes public with gold-based neurology nanotechnologyBiotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat Share XClene goes public with gold-based neurology nanotechnologyhttps://pharmaphorum.com/news/clene-goes-public-with-gold-based-neurology-nanotechnology/
Bridging the gap between pharma and the NHS in MSJanette Curlis is a Multiple Sclerosis Nurse Advisor (MSNA) at Biogen, helping to support the company’s Multiple Sclerosis Share XBridging the gap between pharma and the NHS in MShttps://pharmaphorum.com/views-analysis-patients/bridging-gap-between-pharma-nhs-in-ms/
Lilly to buy private biotech Disarm Therapeutics for up to $1.36bnEli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of Share XLilly to buy private biotech Disarm Therapeutics for up to $1.36bnhttps://pharmaphorum.com/news/lilly-to-buy-private-biotech-disarm-therapeutics-for-up-to-1-36bn/
NICE changes its mind on Novartis’ progressive MS drug MayzentUK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down Share XNICE changes its mind on Novartis’ progressive MS drug Mayzenthttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-progressive-ms-drug-mayzent/
Roche hits back at Novartis with new data for MS drug OcrevusRoche has hit back at Novartis’ newly-approved multiple sclerosis drug Kesimpta, with new data from its already-marketed blockbuster Share XRoche hits back at Novartis with new data for MS drug Ocrevushttps://pharmaphorum.com/news/roche-hits-back-at-novartis-with-new-data-for-ms-drug-ocrevus/
Mission successful for Novartis after FDA approves ofatumumab in MSIt’s mission accomplished for Novartis after the FDA approved ofatumumab for multiple sclerosis, completing a project where the Share XMission successful for Novartis after FDA approves ofatumumab in MShttps://pharmaphorum.com/news/mission-successful-for-novartis-after-fda-approves-ofatumumab-in-ms/
Teva shares slide as it faces illegal kickback charges from US governmentShares in Teva were down sharply this week after the US Department of Justice filed a complaint that Share XTeva shares slide as it faces illegal kickback charges from US governmenthttps://pharmaphorum.com/news/teva-shares-slide-as-it-faces-illegal-kickback-charges-from-us-government/
Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisitionSanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to Share XSanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisitionhttps://pharmaphorum.com/news/sanofi-adds-btk-inhibitors-to-pipeline-with-3-68bn-principia-biopharma-acquisition/
NICE says no to Novartis’ Mayzent in secondary progressive MSThere isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the Share XNICE says no to Novartis’ Mayzent in secondary progressive MShttps://pharmaphorum.com/news/nice-says-no-to-novartis-mayzent-in-secondary-progressive-ms/
